TY  - JOUR
AU  - Edeler, David
AU  - Kaluderovic, Milena R.
AU  - Dojčinović, Biljana
AU  - Schmidt, Harry
AU  - Kaluđerović, Goran N.
PY  - 2016
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/1896
AB  - The anticancer drug cisplatin (CP) is loaded into SBA-15 mesoporous silica (SBA-15 vertical bar CP) and its release from the nanomaterial is studied. The CP-loaded SBA-15 is tested against four tumor cell lines: mouse malignant melanoma B16F10, human adenocarcinoma HeLa, colon HT-29 and prostate PC3. Most importantly, the superiority of this novel material in comparison to CP arises from the fact that the CP-grafted nanomaterial SBA-15 (-> SBA-15 vertical bar CP) is enhancing cessation of proliferation along with induction of senescence in B16F10 in approximately 3.5 times lower concentration. The control material loaded with therapeutically inactive K-2[PtCl4] (-> SBA-15 vertical bar TC) showed no antitumor activity. To a large extent, SBA15| CP-induced senescence might present a safe approach in tumor treatment. Such cells can be cleared by immune cells resulting in efficient tumor regression. So far only apoptotic agents are being exploited in clinics, thus an understanding of the chemotherapeutic-induced senescence will allow oncologists to explore this essential tumor suppressor mechanism.
PB  - The Royal Society of Chemistry
T2  - RSC Advances
T1  - SBA-15 mesoporous silica particles loaded with cisplatin induce senescence in B16F10 cells
VL  - 6
IS  - 112
SP  - 111031
EP  - 111040
DO  - 10.1039/c6ra22596a
ER  - 

@article{
author = "Edeler, David and Kaluderovic, Milena R. and Dojčinović, Biljana and Schmidt, Harry and Kaluđerović, Goran N.",
year = "2016",
abstract = "The anticancer drug cisplatin (CP) is loaded into SBA-15 mesoporous silica (SBA-15 vertical bar CP) and its release from the nanomaterial is studied. The CP-loaded SBA-15 is tested against four tumor cell lines: mouse malignant melanoma B16F10, human adenocarcinoma HeLa, colon HT-29 and prostate PC3. Most importantly, the superiority of this novel material in comparison to CP arises from the fact that the CP-grafted nanomaterial SBA-15 (-> SBA-15 vertical bar CP) is enhancing cessation of proliferation along with induction of senescence in B16F10 in approximately 3.5 times lower concentration. The control material loaded with therapeutically inactive K-2[PtCl4] (-> SBA-15 vertical bar TC) showed no antitumor activity. To a large extent, SBA15| CP-induced senescence might present a safe approach in tumor treatment. Such cells can be cleared by immune cells resulting in efficient tumor regression. So far only apoptotic agents are being exploited in clinics, thus an understanding of the chemotherapeutic-induced senescence will allow oncologists to explore this essential tumor suppressor mechanism.",
publisher = "The Royal Society of Chemistry",
journal = "RSC Advances",
title = "SBA-15 mesoporous silica particles loaded with cisplatin induce senescence in B16F10 cells",
volume = "6",
number = "112",
pages = "111031-111040",
doi = "10.1039/c6ra22596a"
}

Edeler, D., Kaluderovic, M. R., Dojčinović, B., Schmidt, H.,& Kaluđerović, G. N.. (2016). SBA-15 mesoporous silica particles loaded with cisplatin induce senescence in B16F10 cells. in RSC Advances
The Royal Society of Chemistry., 6(112), 111031-111040.
https://doi.org/10.1039/c6ra22596a

Edeler D, Kaluderovic MR, Dojčinović B, Schmidt H, Kaluđerović GN. SBA-15 mesoporous silica particles loaded with cisplatin induce senescence in B16F10 cells. in RSC Advances. 2016;6(112):111031-111040.
doi:10.1039/c6ra22596a .

Edeler, David, Kaluderovic, Milena R., Dojčinović, Biljana, Schmidt, Harry, Kaluđerović, Goran N., "SBA-15 mesoporous silica particles loaded with cisplatin induce senescence in B16F10 cells" in RSC Advances, 6, no. 112 (2016):111031-111040,
https://doi.org/10.1039/c6ra22596a . .

TY  - JOUR
AU  - Bulatović, Mirna
AU  - Kaluderovic, Milena R
AU  - Mojic, Marija
AU  - Zmejkovski, Bojana
AU  - Hey-Hawkins, Evamarie
AU  - Vidakovic, Melita
AU  - Grdovic, Nevena
AU  - Kaluđerović, Goran N.
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela D.
PY  - 2015
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/1650
AB  - (O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV), [PtCl4(iBu(2)eddp)]. shows an improved pharmacological profile in comparison to cisplatin. This is manifested through accelerated dying process led by necrotic cell death, reflected through mitochondrial collapse, strong ATP depletion and reactive oxygen species production. Loss of mitochondrial potential was further followed with intensive apoptosis that finalized with DNA fragmentation. Different dynamic of tumoricidal action could be partly ascribed to less affected repair mechanisms in comparison to cisplatin. Importantly, [PtCl4(iBu(2)eddp)] did not induce necrosis in primary fibroblasts suggesting different intracellular response of normal vs. tumor cells. This selectivity toward malignant phenotype is further confirmed by retained tumoricidal potential in hypoxic conditions, while cisplatin became completely inefficient.
PB  - Elsevier
T2  - European Journal of Pharmacology
T1  - Improved in vitro antitumor potential of (O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV) complex under normoxic and hypoxic conditions
VL  - 760
SP  - 136
EP  - 144
DO  - 10.1016/j.ejphar.2015.04.012
ER  - 

@article{
author = "Bulatović, Mirna and Kaluderovic, Milena R and Mojic, Marija and Zmejkovski, Bojana and Hey-Hawkins, Evamarie and Vidakovic, Melita and Grdovic, Nevena and Kaluđerović, Goran N. and Mijatović, Sanja and Maksimović-Ivanić, Danijela D.",
year = "2015",
abstract = "(O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV), [PtCl4(iBu(2)eddp)]. shows an improved pharmacological profile in comparison to cisplatin. This is manifested through accelerated dying process led by necrotic cell death, reflected through mitochondrial collapse, strong ATP depletion and reactive oxygen species production. Loss of mitochondrial potential was further followed with intensive apoptosis that finalized with DNA fragmentation. Different dynamic of tumoricidal action could be partly ascribed to less affected repair mechanisms in comparison to cisplatin. Importantly, [PtCl4(iBu(2)eddp)] did not induce necrosis in primary fibroblasts suggesting different intracellular response of normal vs. tumor cells. This selectivity toward malignant phenotype is further confirmed by retained tumoricidal potential in hypoxic conditions, while cisplatin became completely inefficient.",
publisher = "Elsevier",
journal = "European Journal of Pharmacology",
title = "Improved in vitro antitumor potential of (O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV) complex under normoxic and hypoxic conditions",
volume = "760",
pages = "136-144",
doi = "10.1016/j.ejphar.2015.04.012"
}

Bulatović, M., Kaluderovic, M. R., Mojic, M., Zmejkovski, B., Hey-Hawkins, E., Vidakovic, M., Grdovic, N., Kaluđerović, G. N., Mijatović, S.,& Maksimović-Ivanić, D. D.. (2015). Improved in vitro antitumor potential of (O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV) complex under normoxic and hypoxic conditions. in European Journal of Pharmacology
Elsevier., 760, 136-144.
https://doi.org/10.1016/j.ejphar.2015.04.012

Bulatović M, Kaluderovic MR, Mojic M, Zmejkovski B, Hey-Hawkins E, Vidakovic M, Grdovic N, Kaluđerović GN, Mijatović S, Maksimović-Ivanić DD. Improved in vitro antitumor potential of (O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV) complex under normoxic and hypoxic conditions. in European Journal of Pharmacology. 2015;760:136-144.
doi:10.1016/j.ejphar.2015.04.012 .

Bulatović, Mirna, Kaluderovic, Milena R, Mojic, Marija, Zmejkovski, Bojana, Hey-Hawkins, Evamarie, Vidakovic, Melita, Grdovic, Nevena, Kaluđerović, Goran N., Mijatović, Sanja, Maksimović-Ivanić, Danijela D., "Improved in vitro antitumor potential of (O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV) complex under normoxic and hypoxic conditions" in European Journal of Pharmacology, 760 (2015):136-144,
https://doi.org/10.1016/j.ejphar.2015.04.012 . .